ALK
7 drugs Oncology
3
approved indications
7
Approved Drugs
6
Companies
5
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 7 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (5 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 2 drugs
PF PRISM CV 1 drug
Takeda 1 drug
By Therapeutic Area
Oncology 6 drugs
Other 1 drugs
By Therapeutic Area
Oncology 6 drugs
XALKORI, ALUNBRIG, ZYKADIA, ALECENSA +2 more
Other 1 drugs
ROZLYTREK
Indications Treated
ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adultsNTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 monthNon-Small Cell Lung CancerAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor